NCT07469384 Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
| NCT ID | NCT07469384 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nathan Kline Institute for Psychiatric Research |
| Condition | SCHIZOPHRENIA 1 (Disorder) |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2030-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-02-01 with a primary completion date of 2030-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the ability of transcranial direct current stimulation (tDCS) applied over the motion processing area of the brain (area MT) to improve face emotion recognition (FER) ability. tDCS is a type of non-invasive brain stimulation in which low level currents are applied over the scalp to influence underlying brain function. In schizophrenia, impaired ability to detect facial motion has been shown to contribute to impaired FER, which, in turn, leads to difficulties in social cognition and poor social outcome. The study will use both fMRI and EEG to measure brain function while participants view moving dot and dynamic face stimuli. Analyses will compare changes in fMRI and EEG activity in individuals receiving active vs. sham stimulation.
Eligibility Criteria
Inclusion Criteria: 1. Male or female subject, age 18-55 2. Competent and willing to sign informed consent 3. No more than moderately ill 4. SCID DSM-5 diagnosis of Sz/SzAff 5. WAIS IQ \>70 6. Does not meet current criteria for DSM-5 defined substance abuse or dependence or have a history of diagnosis within past 6 months 7. On medication within clinically approved range 8. Does not meet criteria for another DSM-5 disorder other than those judged to be minor (e.g. simple phobia) Exclusion Criteria: 1. Significant neurological illness or history of significant head trauma 2. Unstable physical illness or significant auditory/visual deficits that might interfer 3. Contraindication to MRI (e.g. metal implants, claustrophobia, pregnancy) 4. Contraindications to tDCS including metal implant, pacemaker, history of seizure, traumatic brain injury or stroke 5. Significant risk for suicide 6. Has a history of an illness, disease, condition injury, or disability which, in the opinion of the principal investigator, may interfere with the completion of all study requirements per protocol, impact the quality of the data, or the validity of the study results, including unstable physical illness, significant neurological illness, significant head trauma 7. Moderate or greater DSM-5 current substance use disorder, defined based on the presence of 4 or more of 11 substance use criteria within the past 12 months. In addition, individuals for whom substance use leads to not being able to perform work, home or school activities
Contact & Investigator
Daniel C Javitt, MD, PhD
PRINCIPAL INVESTIGATOR
Nathan Kline Institute
Frequently Asked Questions
Who can join the NCT07469384 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying SCHIZOPHRENIA 1 (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07469384 currently recruiting?
Yes, NCT07469384 is actively recruiting participants. Contact the research team at odeta.beggel@nki.rfmh.org for enrollment information.
Where is the NCT07469384 trial being conducted?
This trial is being conducted at Orangeburg, United States.
Who is sponsoring the NCT07469384 clinical trial?
NCT07469384 is sponsored by Nathan Kline Institute for Psychiatric Research. The principal investigator is Daniel C Javitt, MD, PhD at Nathan Kline Institute. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.